Los Angeles – March 29, 2007 — Cancer Therapeutics Laboratories (CTL), a California-based biopharmaceutical company committed to the research, development and commercialization of cancer treating therapies, today announced that it has filed a cross-complaint against Tustin, Calif.-based Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), in a licensing rights dispute over an antibody technology called Tumor Necrosis Therapy […]